Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase
Authors:
- Jingui MaJMJingui Ma
- Jianmei ShiJSJianmei Shi
- Linghua MengLMLinghua Meng
- Hualiang JiangHJHualiang Jiang
- Jian DingJDJian Ding
- Hong LiuHLHong Liu
- 1 July 2010
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 18 (13) , 4615-4624
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Optimization of 7-alkene-3-quinolinecarbonitriles as Src kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2010
- Structure-Based Optimization of Potent and Selective Inhibitors of the Tyrosine Kinase Erythropoietin Producing Human Hepatocellular Carcinoma Receptor B4 (EphB4)Journal of Medicinal Chemistry, 2009
- 9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological EvaluationJournal of Medicinal Chemistry, 2009
- Structure-based virtual screening of Src kinase inhibitorsBioorganic & Medicinal Chemistry, 2009
- 2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure−Activity Relationship Studies toward the Discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan-Src Kinase InhibitorJournal of Medicinal Chemistry, 2006
- The purines: Potent and versatile small molecule inhibitors and modulators of key biological targetsBioorganic & Medicinal Chemistry, 2006
- Pyrazolo[3,4-d]pyrimidines as Potent Antiproliferative and Proapoptotic Agents toward A431 and 8701-BC Cells in Culture via Inhibition of c-Src PhosphorylationJournal of Medicinal Chemistry, 2006
- Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical AssaysJournal of Medicinal Chemistry, 2004
- A renaissance for SRCNature Reviews Cancer, 2004
- Bone-Targeted 2,6,9-Trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseasesBioorganic & Medicinal Chemistry Letters, 2003